PNC Financial Services Group
RAPT

PNC Financial Services Group’s RAPT Therapeutics RAPT Stock Holding History

PNC Financial Services Group’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-497
Closed -$16.8K – 5289
2025
Q4 		$16.8K Hold
497
– – ﹤0.01% 3741
2025
Q3 		$12.8K Hold
497
– – ﹤0.01% 3836
2025
Q2 		$3.98K Sell
497
-6
-1% -$46 ﹤0.01% 4215
2025
Q1 		$4.91K Buy
503
+404
+408% +$3.97K ﹤0.01% 4072
2024
Q4 		$1.25K Buy
99
+89
+890% +$1.13K ﹤0.01% 4387
2024
Q3 		$157 Hold
10
– – ﹤0.01% 4697
2024
Q2 		$238 Buy
+10
New +$462 ﹤0.01% 4640

PNC Financial Services Group's RAPT Position: Q1 2026 in Review

PNC Financial Services Group sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 497 shares — an estimated $16.8K sold.

PNC Financial Services Group first reported a position in RAPT in Q2 2024 and held it in 7 quarters. The position peaked at $16.8K in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • PNC Financial Services Group reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • PNC Financial Services Group sold 497 RAPT Therapeutics shares in Q1 2026, an estimated $16.8K.
  • PNC Financial Services Group first reported a position in RAPT Therapeutics in Q2 2024 and held it in 7 quarters.
  • PNC Financial Services Group's RAPT Therapeutics position peaked at $16.8K in Q4 2025.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.